A detailed history of Logos Global Management LP transactions in Immunovant, Inc. stock. As of the latest transaction made, Logos Global Management LP holds 1,100,000 shares of IMVT stock, worth $30.3 Million. This represents 4.0% of its overall portfolio holdings.

Number of Shares
1,100,000
Previous 575,000 91.3%
Holding current value
$30.3 Million
Previous $15.2 Million 99.35%
% of portfolio
4.0%
Previous 1.42%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$27.51 - $27.51 $14.4 Million - $14.4 Million
525,000 Added 91.3%
1,100,000 $30.3 Million
Q2 2024

Aug 14, 2024

SELL
$25.1 - $31.61 $30.1 Million - $37.9 Million
-1,200,000 Reduced 67.61%
575,000 $15.2 Million
Q1 2024

May 15, 2024

BUY
$30.27 - $43.79 $17.4 Million - $25.2 Million
575,000 Added 47.92%
1,775,000 $57.4 Million
Q4 2023

Feb 14, 2024

SELL
$31.31 - $44.19 $12.5 Million - $17.7 Million
-400,000 Reduced 25.0%
1,200,000 $50.6 Million
Q3 2023

Nov 14, 2023

SELL
$18.55 - $39.96 $12.1 Million - $26 Million
-650,000 Reduced 28.89%
1,600,000 $61.4 Million
Q2 2023

Aug 14, 2023

SELL
$14.2 - $23.75 $3.55 Million - $5.94 Million
-250,000 Reduced 10.0%
2,250,000 $42.7 Million
Q1 2023

May 15, 2023

SELL
$15.27 - $19.72 $9.93 Million - $12.8 Million
-650,000 Reduced 20.63%
2,500,000 $38.8 Million
Q4 2022

Feb 14, 2023

BUY
$6.59 - $17.75 $20.8 Million - $55.9 Million
3,150,000 New
3,150,000 $55.9 Million
Q3 2020

Nov 16, 2020

SELL
$22.61 - $38.9 $14.1 Million - $24.3 Million
-625,000 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$13.87 - $28.44 $8.67 Million - $17.8 Million
625,000 New
625,000 $15.2 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Logos Global Management LP Portfolio

Follow Logos Global Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Logos Global Management LP with notifications on news.